231 related articles for article (PubMed ID: 26160817)
1. [Neuropathology of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy].
Kanda T
Brain Nerve; 2015 Jul; 67(7):891-901. PubMed ID: 26160817
[TBL] [Abstract][Full Text] [Related]
2. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
Metz I; Radue EW; Oterino A; Kümpfel T; Wiendl H; Schippling S; Kuhle J; Sahraian MA; Gray F; Jakl V; Häusler D; Brück W
Acta Neuropathol; 2012 Feb; 123(2):235-45. PubMed ID: 22057786
[TBL] [Abstract][Full Text] [Related]
3. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
4. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
[TBL] [Abstract][Full Text] [Related]
5. In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection.
Martin-Blondel G; Bauer J; Cuvinciuc V; Uro-Coste E; Debard A; Massip P; Delisle MB; Lassmann H; Marchou B; Mars LT; Liblau RS
Neurology; 2013 Sep; 81(11):964-70. PubMed ID: 23935178
[TBL] [Abstract][Full Text] [Related]
6. Advances in the management of PML: focus on natalizumab.
Fox R
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
[TBL] [Abstract][Full Text] [Related]
7. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
8. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
[TBL] [Abstract][Full Text] [Related]
10. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Carruthers RL; Chitnis T; Healy BC
Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
[TBL] [Abstract][Full Text] [Related]
11. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.
Wüthrich C; Popescu BF; Gheuens S; Marvi M; Ziman R; Denq SP; Tham M; Norton E; Parisi JE; Dang X; Lucchinetti CF; Koralnik IJ
J Neuropathol Exp Neurol; 2013 Nov; 72(11):1043-51. PubMed ID: 24128680
[TBL] [Abstract][Full Text] [Related]
13. Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
Scarpazza C; Prosperini L; Mancinelli CR; De Rossi N; Lugaresi A; Capobianco M; Moiola L; Naldi P; Imberti L; Gerevini S; Capra R
J Neurol Sci; 2017 Jul; 378():233-237. PubMed ID: 28566170
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.
Schwab N; Schneider-Hohendorf T; Wiendl H
Int Immunol; 2015 Jan; 27(1):47-53. PubMed ID: 25326459
[TBL] [Abstract][Full Text] [Related]
15. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
Hunt D; Giovannoni G
Pract Neurol; 2012 Feb; 12(1):25-35. PubMed ID: 22258169
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.
Berger JR; Houff S
Neurol Res; 2006 Apr; 28(3):299-305. PubMed ID: 16687057
[TBL] [Abstract][Full Text] [Related]
18. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy.
Vendrely A; Bienvenu B; Gasnault J; Thiebault JB; Salmon D; Gray F
Acta Neuropathol; 2005 Apr; 109(4):449-55. PubMed ID: 15739098
[TBL] [Abstract][Full Text] [Related]
19. Immunological and clinical consequences of treating a patient with natalizumab.
Schwab N; Höhn KG; Schneider-Hohendorf T; Metz I; Stenner MP; Jilek S; Du Pasquier RA; Gold R; Meuth SG; Ransohoff RM; Brück W; Wiendl H
Mult Scler; 2012 Mar; 18(3):335-44. PubMed ID: 21908480
[TBL] [Abstract][Full Text] [Related]
20. Progressive multifocal leukoencephalopathy.
Weissert R
J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
